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There has been much advocacy for the implementation of
screening strategies for asymptomatic atrial fibrillation
(AF),1 given the high health care burden associated with
this common arrhythmia.2 Importantly, AF can occur asymp-
tomatically in up to 40% of the cases, even though no
profound differences were reported between symptomatic
and asymptomatic AF patients in terms of risk for adverse
outcomes.3,4 Based on this evidence, implementing screen-
ing strategies to effectively identify unknownAF patients has
highlighted how structured screening strategies are effective
in identifying a higher number of high-risk AF patients
needing the prescription of oral anticoagulants (OACs), and
that using such strategies to increase OAC can be cost-
effective.5–7 Notwithstanding this, most of the studies
reported thus far have only focused on the diagnostic yield
related to the screening procedure and were not designed or
powered to identify a significant clinical benefit in reducing
adverse events in screened patients compared with those
incidentally diagnosed with AF.1 On the basis of this lack of
evidence, in 2018 the United States Preventive Services Task
Force (USPSTF) released a statement which still did not
recommend the use of large-scale systematic screening
strategies to identify AF patients.8,9
In this issue of Thrombosis and Haemostasis, Wallenhorst
and colleagues present an interesting and topical analysis10
derived from the United Kingdom Clinical Practice Research
Datalink, linked to the Hospital Episodes Statistics and the
Office for National Statistics to gather information regarding
hospital admissions andmortality data. In this analysis using
International Classification of Diseases-10th Revision codes,
the authors analyzed 22,035 adult (18–84 years old) subjects
with incident AF from January 1, 2001 to October 31, 2009
categorized according to themode of AF detection. Hence, the
patients were divided as follows: (1) asymptomatic inciden-
tally detected ambulatory AF (AA-AF) [N¼5,409, 24.5%)]; (2)
symptomatic ambulatory AF (SA-AF) [N¼5,913, 26.8%]; (3) AF
as primary hospital discharge diagnosis (PH-AF) [N¼4,989,
22.6%); (4) AF as nonprimary hospital discharge diagnosis
(Non-PH-AF) [N¼26.0%]. The study cohort was then analyzed
and compared with 23,605 non-AF matched patients, regard-
ing the occurrence of stroke and all-cause death during long-
term follow-up. At baseline, AA-AF patients were found to be
less affected by comorbidities, with an overall low thrombo-
embolic risk, similarly tonon-AFpatients. Conversely, thenon-
PH-AF group showed the highest burden of comorbidities and
the highest level of thromboembolic risk. SA-AF and PH-AF
patients showedamixedclinical profilebeingbothmoderately
comorbid, but with PH-AF ones being younger and with the
lowest thromboembolic risk. Over a 3-year follow-up, while
the non-AF group was associated to lower risk of stroke
occurrence, in a fully adjusted competitive risk analysis com-
paredwith the AA-AF group, all the other three groups (SA-AF,
PH-AF, and Non-PH-AF) reported no differences in the associ-
ationwith stroke events, as compared with the asymptomatic
patients.10 Similar results were found when restricting the
observation to high-risk patients only (males with CHA2DS2-
VASc 2 and females with CHA2DS2-VASc 3).
Non-AF subjects were associatedwith a lower risk and the
SA-AFandPH-AFonesshowednodifference inassociationwith
all-cause death; however, non-PH-AF patients were associated
with a higher risk of all-cause death compared with asymp-
tomatic patients. Notably, the rate of OAC prescription was
generally low (29%), with no differences between low- and
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OAC prevalence, while non-PH-AF subjectsweremarkedly less
treated with OAC (20%).
This article allows us to highlight several important
considerations regarding the modern management of AF
patients. First, even in an unselected real-world cohort of
subjects with first diagnosed AF, the proportion of patients
with completely asymptomatic AF, which were only inciden-
tally diagnosed, remains quite consistent, being around one-
quarter of the entire study cohort. Even though those
patients appeared to be slightly less burdened with comor-
bidities, they still have an important thromboembolic risk
with more than 70% with a CHA2DS2-VASc score 2. Indeed,
stroke risk changes with aging and incident comorbid-
ities11,12 and the burden of symptoms does not necessarily
influence the risk of outcomes, even in those who never have
been symptomatic4; hence, asymptomatic AF patients
should not be less intensively treated in comparison with
symptomatic subjects.3
Second, no differences in the risks of ischemic stroke
between asymptomatic presentation of AF and other pre-
sentations have important clinical correlates regarding the
application of opportunistic and/or systematic screening
procedures in the general population. Indeed, those 5,409
asymptomatic patientswhowere found to be in AFwere only
accidentally diagnosed, mimicking what could be obtained
by using an opportunistic screening applied to the entire
population. If such patients had not been found in AF, none of
them could have been prescribed with OAC and then an even
larger number of strokes would have been recorded. In the
2020 European Society of Cardiology (ESC) clinical guide-
lines, the need for screening has been strongly emphasized.13
Notwithstanding this, the ESC guidelines still recommend
the use of opportunistic screening only in patients age 65
years, even though with a “B” level of evidence, while the use
of systematic screening is suggested to be considered in
subjects 75 years or with a high burden of stroke risk
factors, again with a low quality of evidence (class II, level
B).13 Currently the USPSTF is considering an update of its
recommendations about screening strategies for AF (https://
www.uspreventiveservicestaskforce.org/uspstf/draft-re-
commendation/screening-atrial-fibrillation), and while this
update is still ongoing, the evidence review still underlines
that the direct evidence regarding the benefit of AF screening
is still lacking, since no completed trials have assessed the
benefits and harms of anticoagulation treatment among
screen-detected AF. Consequently, systematic population
screening for AF is still not recommended.
This situation appears paradoxical, given the large evi-
dence regarding the positive diagnostic yield obtained by
screening strategies1,5 and with a “major” scientific society
recommending AF screening, even though with a low degree
of direct evidence. This situation is due to the lack of solid
data regarding the reduction of adverse clinical outcomes in
subjects undergoing screening. Indeed, most of the studies
published thus far focused exclusively on the diagnostic
yield, not considering the long-term follow-up. Only few
studies (►Table 1, upper panel) currently report data about
adverse events, again with conflicting and inconsistent data.
While some of the studies were small in size and reported a
very low number of events with little or no differences
between subjects diagnosed by screening and by usual
care,14,15 other recent data seem to indicate a more signifi-
cant benefit. The follow-up data from the STROKESTOP
program, recently presented during the European Heart
Rhythm Association 2021 online congress, showed a signifi-
cant reduction of the composite outcome of adverse events,
even though the Kaplan–Meier curves appeared to diverge
only after 4 years of follow-up and with a small reduction in
terms of relative risk.16 Conversely, the mSToPS trial17 seems
to indicate a more important reduction of the risk over the
3 years of follow-up.
Additionally, more data are needed on the effects of
screening on patient anxiety, as a consequence of a positive
screening, as one of the criticisms raised by the first assess-
ment done by the USPSTF,9 even if it is reasonable to expect
that this can be easily managed through adequate patient
information in the context of a clinically structured integrat-
ed approach.18 The current scenario suggests that even if the
efficacy of screening in terms of diagnostic yield is quite
solidly reported by several studies, the real impact on risk
reduction is yet to be determined.
In the next few years, at least four large studies specifically
investigating this issue would ultimately clarify whether to
diagnose AF by screening campaigns would be useful or not
(►Table 1, lower panel). Indeed, the STROKESTOP II,19,20 the
SAFER (ISRCTN Registry: ISRCTN72104369), the GUARD-AF
(ClinicalTrials.gov: NCT04126486), and the HEARTLINE
(ClinicalTrials.gov: NCT04126486) studies all are going to
include very large number of patients and have been specifi-
cally conceived and powered to determine the impact of the
screening strategies on clinical events.
Last, while the absence of a significant difference in all-
cause mortality between AA-AF, SA-AF, and PH-AF patients
only emphasizes what we discussed above, regarding the
evidence that those patients found in AF during hospitali-
zation, but not as primary diagnosis, have a higher risk of
all-cause death. This allows us to further emphasize the
need for more structured management of “clinically com-
plex AF” patients. The burden of clinical complexity is
associatedwith AF pathophysiology and arrhythmia course
over time,21 as well as with an increased risk of adverse
outcomes (particularly all-cause death)22,23 and the pre-
scription and quality of OAC therapy.22–24 Despite the
significant uptake of OAC observed in recent years and
the consequential reduction of stroke risk,25 the risk of all-
cause death has remained steadily high over the years, but
has also increased in terms of absolute numbers.26,27 The
recent ESC guidelines have underlined the importance to
manage AF patients in an integrated and holistic way, by
using the “Atrial fibrillation Better Care (ABC)” pathway,
which was proposed to streamline the application of inte-
grated care in AF patients28 with a major impact on reduc-
ing AF-related mortality, stroke, bleeding, and
hospitalizations.29–32 Wider application of the ABC path-
way, together with a better AF patient evaluation and
characterization using the 4S-AF scheme,33 will help






























Table 1 Current and future studies about AF screening strategies and risk of adverse outcomes
Current studies
Study Year Study design N Outcomes Main results
REHEARSE-AF14 2017 65 year subjects with
CHA2DS2-VASc 2 with no
AF and no OAC or pacing
randomized to 30 seconds
single-lead handheld ECG twice
weekly or usual care
1,004 Clinical events at
1 year FU
Despite a numerically lower
number of most of the clinical
events examined, no
significant difference was
found between the two
groups
Engdahl15 2018 74–75 year-old inhabitants from
one Swedish municipality
screened with 12-lead ECGþ
handheld ECG for 2 weeks
106 Ischemic stroke at
5 year FU
At 5-year follow-up rates of
ischemic stroke significantly
decreased in the screening
area, while no changes were
found in a control geographical
area where no screening had
been performed
STROKESTOP16,34 2021 All residents from 2 Swedish
regions aged 75–76 randomized
to single-lead ECG twice daily for






at 5 year FU
Subjects randomized to
screening had a lower risk of
the composite endpoint
throughout the follow-up
observation (HR: 0.96, 95%
CI: 0.920–0.999, p¼0.045)a
mSToPS17,35 2021 Claims database participants
75 years or males 55
years/females  65 years with
one risk factor/comorbidity ran-
domized in 1:2 ratio to ECG skin
patches monitoring for 2 weeks






at 3 years FU
Subjects randomized to
screening has a lower risk of
the combined endpoint (8.4
vs. 13.8 per 100 person-years;
HR: 0.53, 95% CI: 0.40–0.78;
p<0.01)b
Future studies
Study Year Study design N Outcomes Trial registration
STROKESTOP
II19,20
2017 75–76 years Stockholm region
inhabitants, randomized to
receive screening procedure or
usual care; subjects randomized
to screening were assigned to
handheld ECG monitoring either
intermittent for 2 weeks or
one-stop screening according to
NT-proBNP levels






over 5 year FU
ClinicalTrials.gov:
NCT02743416
SAFER 2017 70 year subjects from a primary
care unit network randomized to
receive screening through a
single-lead handheld ECG 4 times
daily for 3 weeks; the study
comprises two feasibility phases
and one large interventional trial
126,000 Ischemic and
haemorrhagic
stroke over 5 years
of FU
ISRCTN: ISRCTN72104369
GUARD-AF 2019 70 year subjects from a
primary care unit network
randomized to receive screening
through an ECG skin patch with
no AF and no OAC







HEARTLINE 2020 65 year-old subjects
randomized to receive screening
through a smart watch device
and a healthy heart engagement
program
150,000 Composite of cere-
brovascular events
and all-cause death
over 3 years of FU
ClinicalTrials.gov:
NCT04126486
Abbreviations: AF, atrial fibrillation; CI, confidence interval; ECG, electrocardiogram; FU, follow-up; HR, hazard ratio; NT-proBNP, N-terminal
prohormone of brain natriuretic peptide; OAC, oral anticoagulant.
aData on outcomes presented at the European Heart Rhythm Association 2021 Online Congress, not yet fully published.
bData on outcomes presented at the American Heart Association Scientific Sessions 2020, not yet fully published.






























improve our management and reduce the risk of adverse
clinical events in AF patients.
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